Med Check |
May 03, 2013
Otsuka Pharmaceutical and Lundbeck announced February 28 the FDA approval of Abilify Maintena, an extended-release injectable suspension of aripiprazole, as an intramuscular depot formulation indicated for the treatment of schizophrenia.
...[Read More]